Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy, Safety and Immunogenicity of GVGH Shigella Sonnei Vaccine (1790GAHB) in a Human Challenge Study of Healthy Non-immune Adults

Trial Profile

Efficacy, Safety and Immunogenicity of GVGH Shigella Sonnei Vaccine (1790GAHB) in a Human Challenge Study of Healthy Non-immune Adults

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 14 Dec 2018

At a glance

  • Drugs Shigella sonnei vaccine (Primary)
  • Indications Shigella infections
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 05 Dec 2018 The original study protocol has been amended due to requests from the FDA, requests from the funder of the study, Bill & Melinda Gates Foundation (BMGF), and to further align the protocol to other GSK studies and to the challenge model established at the Cincinnati Children's Hospital Medical Centre.
    • 05 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 28 Jun 2018 Planned End Date changed from 9 Oct 2019 to 21 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top